logo-loader
viewAmryt Pharma PLC

Investor Update: Amryt Pharma's AP101 given fast-track status by US regulator

Headlines from the Proactive UK newsroom.

Amryt Pharma (LON:AMYT) has received fast track designation from the US FDA for its treatment for skin disease EB. The FDA recognised that EB is a serious disease and that there are no FDA-approved treatments for this condition.

Shanta Gold (LON:SHG) has intersected high grades over sizeable widths from its latest surface exploration drilling at the New Luika mine in Tanzania. Shanta said these results coupled with the next round of drilling should be sufficient to declare new resources at two new targets in future 

Anglo Asian Mining (LON:AAZ) has entertained a delegation from the British Embassy in Azerbaijan at its Gedabek gold, copper and silver mine. Anglo Asian’s the largest mining investor in Azerbaijan and the second largest British investor after BP.

Argos chief executive John Rogers is to leave the Sainsbury’s subsidiary to become chief financial officer of ad group WPP. Rogers’ last day will be 31 October.

Bakery chain Greggs has racked up another quarter of impressive sales. Revenues rose by 12% in the three months to September and by 7.4% on a like-for-like basis. Greens also opened its 2,000th outlet during the period. 

JD Sports’ acquisition of Footasylum is to face a full competition authority inquiry. JD firmly believes there will no impact on competition so offered no remedies to avoid a full reference, hence the CMA today confirmed there will be a phase 2 investigation.

Quick facts: Amryt Pharma PLC

Price: 122.5 GBX

AIM:AMYT
Market: AIM
Market Cap: £193.21 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Amryt Pharma PLC named herein, including the promotion by the Company of Amryt Pharma PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Amryt Pharma well positioned to become 'global leader in...

Amryt Pharma PLC's (LON:AMYT) Rory Nealon talks Proactive London's Andrew Scott through their trading update for the nine months to the end of September 2019. It's a period in which Amryt completed the acquisition of Aegerion Pharmaceuticals Inc and saw the firm go from a single-product,...

6 days, 17 hours ago

RNS

Grant of Options

6 days, 11 hours ago

Trading Update

6 days, 23 hours ago

Notice of Trading Update

1 week, 1 day ago

Holding(s) in Company

2 weeks, 1 day ago

Holdings in Company

on 3/10/19

Half-year Report

on 30/9/19

2 min read